Transcranial Direct Current Stimulation (tDCS) in Different Psychiatric Disorders
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Menoufia University
- Enrollment
- 320
- Locations
- 1
- Primary Endpoint
- Montgomery-Åsberg Depression Rating Scale
Study Overview
Brief Summary
The goal of this clinical trial is to evaluate the efficacy and safety of transcranial direct current stimulation (tDCS) in reducing core symptoms of different psychiatric disorders using validated clinical scales.
- To assess response and remission rates.
- To evaluate the durability of treatment effects over follow-up.
- To examine effects on cognition, daily functioning, and quality of life.
- To monitor tolerability and adverse events.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 16 Years to 65 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age between 16 and 65 years
- •Fulfillment of DSM-5 diagnostic criteria for one of the target disorders
- •Stable pharmacological treatment for at least four weeks prior to enrollment (if applicable)
- •Ability to provide informed consent
Exclusion Criteria
- •History of epilepsy or seizures
- •Presence of intracranial metallic implants or implanted electronic devices
- •Severe neurological disorders (e.g., brain tumors)
- •Pregnancy
- •Active substance use disorder
- •Severe cognitive impairment or comorbid psychiatric disorders interfering with assessment
Arms & Interventions
A comparative cross-sectional study: Obsessive-Compulsive Disorder
- SMA (Cz) or OFC (Fp1/Fp2)
- Anode: Cz/Fp1, Cathode: contralateral shoulder
- 2 mA 20 min
- 10-20
Intervention: tDCS Parameters (Device)
A comparative cross-sectional study: Schizophrenia
- Left TPJ (P3) + Left DLPFC (F3)
- Anode: P3, Cathode: F3 (for hallucinations)
- 2 mA 20 min
- 10-15
Intervention: tDCS Parameters (Device)
A comparative cross-sectional study ; Generalized Anxiety Disorder
- Right DLPFC (F4) or vmPFC
- Anode: F4, Cathode: left DLPFC (F3)
- 2 mA -Session duration: 20-30 minutes per session.
- 10
Intervention: tDCS Parameters (Device)
comparative cross-sectional study; Insomnia
- Left DLPFC (F3) or Parietal (Pz)
- Anode: F3/Pz, Cathode: contralateral supraorbital
- 2 mA -Session duration: 20-30 minutes per session.
- 10 -12
Intervention: tDCS Parameters (Device)
A comparative cross-sectional study: Major Depressive Disorder
- Left DLPFC (F3) Anode: F3, Cathode: right supraorbital
- 2 mA 20-30 min
- 10 -20 daily )
Intervention: tDCS Parameters (Device)
Outcomes
Primary Outcomes
Montgomery-Åsberg Depression Rating Scale
Time Frame: The assessment period for each participant was 24 weeks from the start of their participation in the study.
Depression severity was assessed using the Montgomery-Åsberg Depression Rating Scale. The total scores on this scale range from a minimum of 0 to a maximum of 60, with higher scores indicating a greater severity of depressive symptoms (a worse outcome)
Positive and Negative Syndrome Scale
Time Frame: The assessment period for each participant was 24 weeks from the start of their participation in the study.
Symptom severity was evaluated using the Positive and Negative Syndrome Scale. Total scores on this scale range from a minimum of 30 to a maximum of 210, with higher scores indicating a greater severity of symptoms (a worse outcome).
Secondary Outcomes
- Yale-Brown Obsessive Compulsive Scale(The assessment period for each participant was 24 weeks from the start of their participation in the study.)
- Generalized Anxiety Disorder-7(The assessment period for each participant was 24 weeks from the start of their participation in the study.)
- Insomnia Severity Index - 7 items(The assessment period for each participant was 24 weeks from the start of their participation in the study.)
Investigators
SSalah el-bahy
Fellow Professor
Menoufia University